Delayed haemolytic transfusion reaction caused by anti-M antibody in a patient receiving interleukin-2 and interferon for metastatic renal cell cancer

Clinical and Laboratory Haematology

Volumn 21, Issue 6, 1999, Pages 407-408

  Parry Jones, N ^a   Gore, M E ^a   Taylor, J ^b   Treleaven, J G ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

Anti M antibody; Delayed haemolytic transfusion reaction; Interferon; Interleukin 2

Indexed keywords

IMMUNOGLOBULIN M ANTIBODY; INTERFERON; INTERLEUKIN 2;

ADULT; ANTIBODY DETECTION; ANTIGEN PRESENTATION; ARTICLE; BLOOD TRANSFUSION REACTION; CASE REPORT; CROSS REACTION; DRUG EFFECT; HEMOLYSIS; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER FUNCTION; MALE; MONONUCLEAR CELL; NEPHRECTOMY; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; CARCINOMA, RENAL CELL; HEMOLYSIS; HUMANS; IMMUNOGLOBULIN M; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS;

EID: 0033392319     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.1999.00260.x     Document Type: Article

References (7)

1. Alperin J.B., Riglin. H., Branch D.R., Gallagher M.T. & Petz L.D. (1983) Anti-M causing delayed haemolytic transfusion reaction. Transfusion 23, 322-324.
2. BCSH Blood Transfusion Task Force (Chairman: J.A.F. Napier) (1996) Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. Transfusion Medicine 6, 273-283.
3. Furlong M.B. & Monaghan W.P. (1981) Delayed haemolytic episodes due to anti-M. Transfusion 21, 45-49.
4. Mollison P.L., Engelfriet C.P. & Contreras M., eds. (1997) Blood Transfusion in Clinical Medicine, 10th edn. pp. 196-199. Oxford, Blackwell Science.
5. Sancho J.M., Pujol M., Fernandez F., Soler M., Manzano P. & Feliu E. (1998) Delayed haemolytic transfusion reaction due to anti-M antibody. British Journal of Haematology 103, 268-269.
6. Tourani J.M., Pfister C., Berdah J.F. et al. (1998) Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Journal of Clinical Oncology 16, 2505-2513.
7. Vaughan. M., Johnston S.R.D., Moore J.S. & Gore M.E. (1997) A phase II study of subcutaneous interleukin-2, α interferon and prolonged venous infusional 5-FU in patients with metastatic renal cell cancer. British Journal of Cancer 76, 50 (APO45).